Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

Israeli startup Exodigo, which develops underground scanning systems for construction and infrastructure companies, based on ...

Limitless X Holdings, Inc. (OTCQB: LIMX), a leading Wellness and Lifestyle Performance company, today announced that it has ...